Manufacturing of non-viral and viral vectors for ex vivo and in vivo gene therapy continues to present a major bottleneck, particularly for human clinical trials, but also for preclinical evaluation. Likewise, variations in protocols used to produce and purify vectors might impact on efficacy of cell transduction and/or cell responses, and thus detracts from the comparability of results from different groups.

Given this obvious importance, Human Gene Therapy Methods is calling for original research papers, review articles, as well as protocols, to appear in a special issue on Manufacturing and Quality control. Contributions in the following areas are welcome:

• Development of novel producer cell lines or production strategies
• Comprehensive comparison of existing production protocols
• Development of novel purification strategies for vectors or vector-treated cells
• GMP production technologies or protocols for vectors or vector-treated cells
• Comprehensive analyses of storage conditions
• Development of novel or significant improvements of current protocols for characterizing vector preparations regarding titer and/or contamination
• QC protocols, with special attention to newer methods such as next-generation sequencing (NGS)

Benefits of publishing in Human Gene Therapy Methods:

• Rapid, high-quality peer review
• Open Access options available
• Fast and user-friendly electronic submission
• Maximum exposure: accessible in 170 countries worldwide
• Competitive author benefits program